Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
17 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Pharming Group N.V.’s names, not what it holds today.
Patents granted
17
15 utility, 2 reissue, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
21
since 2001, to Dec 31, 2025
Names they are printed under
4
a subsidiary
By yearGrantedApplications published
'09'10'11'12'13'14'15'16'17'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Pharming Intellectual Property B.V. a subsidiary
NL, as the owner printed on each patent
16 publishedABLIVA AB a subsidiary
SE, as the owner printed on each patent
0 publishedABLIVA AB a subsidiary
named as the applicant on its applications, in SE
4 publishedPharming Intellectual Property B.V. a subsidiary
named as the applicant on its applications, in NL
1 publishedNames not counted (1)
ProBio, Inc.
Most of its patents print NO; this name counts in US. 0 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| May 27, 2025 | 12,310,940 | Cell-permeable succinate compounds | Pharmaceuticals | ABLIVA AB |
| Dec 10, 2024 | 12,162,824 | Succinate prodrug, compositions containing the succinate prodrug and uses thereof | Pharmaceuticals | ABLIVA AB |
| Jan 31, 2023 | 11,565,998 | Succinate prodrug, compositions containing the succinate prodrug and uses thereof | Pharmaceuticals | ABLIVA AB |
| Oct 19, 2021 | 11,147,789 | Cell-permeable succinate compounds | Pharmaceuticals | ABLIVA AB |
| Dec 8, 2020 | 10,857,150 | Use of sanglifehrin macrocyclic analogues as anticancer compounds | Pharmaceuticals | ABLIVA AB |
| Jan 17, 2017 | 9,546,381 | Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals | Biotechnology | Pharming Intellectual Property B.V. |
| Aug 9, 2016 | 9,408,366 | Milking device | Other special machines | Pharming Intellectual Property B.V. |
| Dec 15, 2015 | 9,211,318 | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury | Pharmaceuticals | Pharming Intellectual Property B.V. |
| Apr 9, 2013 | 8,415,288 | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury | Pharmaceuticals | Pharming Intellectual Property B.V. |
| Sep 25, 2012 | RE43,691 | C1 inhibitor with short half-life transient treatment | | Pharming Intellectual Property B.V. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 17, 2024 | 2024/0342258 | USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED SYMPTOMS | Pharmaceuticals | Pharming Intellectual Property B.V. |
| Aug 29, 2024 | 2024/0285736 | Treatment and prevention of pre-eclampsia | Pharmaceuticals | Pharming Intellectual Property B.V. |
| Jul 18, 2024 | 2024/0238255 | KL1333 FOR USE IN MEDICINE | Pharmaceuticals | ABLIVA AB |
| Jul 27, 2023 | 2023/0235023 | USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS | Pharmaceuticals | Pharming Intellectual Property B.V. |
| Feb 2, 2023 | 2023/0033294 | SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF | Pharmaceuticals | ABLIVA AB · patent 12,162,824 granted from it |
| May 26, 2022 | 2022/0162162 | SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF | Pharmaceuticals | ABLIVA AB · patent 11,565,998 granted from it |
| Dec 30, 2021 | 2021/0401792 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Pharmaceuticals | ABLIVA AB · patent 12,310,940 granted from it |
| Oct 21, 2021 | 2021/0324107 | USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS | Pharmaceuticals | Pharming Intellectual Property B.V. |
| Dec 17, 2020 | 2020/0390872 | Treatment and prevention of pre-eclampsia | Pharmaceuticals | Pharming Intellectual Property B.V. |
| Dec 25, 2014 | 2014/0373786 | MILKING DEVICE | Other special machines | Pharming Intellectual Property B.V. · patent 9,408,366 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.